Preferable timing of therapeutic drug monitoring in patients with impaired renal function treated with once-daily administration of vancomycin

Journal of Infection and Chemotherapy

Volumn 19, Issue 4, 2013, Pages 709-716

  Takahashi, Yoshiko ^a   Takesue, Yoshio ^a   Takubo, Shingo ^a   Ishihara, Mika ^a   Nakajima, Kazuhiko ^a   Tsuchida, Toshie ^a   Ikeuchi, Hiroki ^b   Uchino, Motoi ^b  

^a HYOGO COLLEGE OF MEDICINE HOSPITAL   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Impaired renal function; Methicillin resistant Staphylococcus aureus (MRSA); Therapeutic drug monitoring (TDM); Trough concentration; Vancomycin (VCM)

Indexed keywords

CREATININE; VANCOMYCIN;

ABDOMINAL INFECTION; ADULT; AGED; ARTICLE; BLOODSTREAM INFECTION; BONE INFECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MONITORING; EAR INFECTION; FEMALE; FOLLOW UP; HUMAN; INFECTION; INFECTIOUS ARTHRITIS; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; RESPIRATORY TRACT INFECTION; SERUM TROUGH CONCENTRATION; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY TRACT INFECTION;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG MONITORING; ENTEROCOCCUS FAECALIS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS; VANCOMYCIN;

EID: 84882253045     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-013-0551-7     Document Type: Article

References (14)

1. Liu C, Graber CJ, Karr M, Diep BA, Basuino L, Schwartz BS, et al. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Clin Infect Dis. 2008;46:1637-46.
2. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298:1763-71.
3. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666-74.
4. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285-92.
5. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52:1330-6.
6. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166:2138-44.
7. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82-98.
8. Rowland M, Tozer TN. Therapeutic regimens. In: Rowland M, Tozer TN, editors. Clinical pharmacokinetics and pharmacodynamics. Concepts and applications. IV ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2011. p. 245-329.
9. Winter ME. Basic principles. In: Winter ME editor. Basic clinical pharmacokinetics, 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2010. p. 2-132.
10. Teramachi H, Hatakeyama H, Matsushita R, Imai Y, Miyamoto K, Tsuji A. Evaluation of predictability for vancomycin dosage regimens by the Bayesian method with Japanese population pharmacokinetic parameters. Biol Pharm Bull. 2002;25:1333-8.
11. Lake KS, Peterson CD. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy. 1985;5:340-4.
12. Matzke GR, Kovarik JM, Rybak MJ, Boike SC. Evaluation of the vancomycin-clearance: creatinine-clearance relationship for predicting vancomycin dosage. Clin Pharm. 1985;4:311-5.
13. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest. 2006;130:947-55.
14. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52:3315-20.